[ad_1]
New York, March 03, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Immunosuppressants Global Market Report 2022” — https://www.reportlinker.com/p06241886/?utm_source=GNW
A.
The global immunosuppressants market is expected to grow from $16.54 billion in 2021 to $19.52 billion in 2022 at a compound annual growth rate (CAGR) of 18%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $34.05 billion in 2026 at a CAGR of 14.9% .
The immunosuppressant market consists of sales of immunosuppressants or anti-rejection drugs generated by companies manufacturing immunosuppressant drugs. Immunosuppressants are medicinal substances that prevent or inhibit activity in the immune system.
Immunosuppressive drugs are mainly used in organ transplantation procedures and also in the treatment of certain autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and others.
The main classes of drugs in immunosuppressants are corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents and others. Monoclonal antibodies are created by cloning a single white blood cell.
Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different indications include organ transplantation, autoimmune disorders, non-autoimmune inflammatory diseases and is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North …
Full story available on Benzinga.com
[ad_2]
Source link
